Is C-peptide a predictor of severity of coronary artery disease in metabolic syndrome? An observational study.

What Was Tested

Researchers studied C-Peptide in this observational study publication.

SYNTAX scoring was done to assess the severity of coronary artery disease in groups 1a and 1b.

Why It Was Studied

Various cardiovascular disease (CVD) risk factors have been implicated to correlate with the severity of the disease.

Present study was conducted to correlate one such risk factor i.e. fasting serum C-peptide with the presence or absence and the severity of CVD in Indian population.

Who Took Part

The study group was 68 patients.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

68 patients with metabolic syndrome who underwent coronary angiogram for suspected CVD were included.

How the Study Was Run

Their fasting serum C-peptide levels were measured in addition to routine biochemical and cardiological tests.

They were divided into 2 groups - those with a positive coronary angiography findings (Group 1) and those with normal coronary angiograms (Group 2).

The former group was further divided into those with an Acute Coronary Syndrome (ACS) (Group 1a) and those with Chronic Stable Angina (CSA) (Group 1b).

Levels of C-peptide were compared between the groups.

What Was Measured

PubMed files the paper under topics including Biomarkers, C-Peptide, Coronary Angiography, Coronary Artery Disease, Incidence, India and Metabolic Syndrome.

Author keywords: Insulin resistance and SYNTAX score.

What This Means in Plain Language

This is an observational study of C-Peptide in 68 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Indian heart journal), a journal based in India.

More context: the C-Peptide compound page, all human trials.